Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 2.79
WX's Cash to Debt is ranked higher than
73% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. WX: 2.79 )
WX' s 10-Year Cash to Debt Range
Min: 0.33   Max: No Debt
Current: 2.79

Equity to Asset 0.72
WX's Equity to Asset is ranked higher than
82% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. WX: 0.72 )
WX' s 10-Year Equity to Asset Range
Min: -0.32   Max: 0.8
Current: 0.72

-0.32
0.8
Interest Coverage 53.89
WX's Interest Coverage is ranked higher than
67% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 257.77 vs. WX: 53.89 )
WX' s 10-Year Interest Coverage Range
Min: 6.71   Max: 9999.99
Current: 53.89

6.71
9999.99
F-Score: 5
Z-Score: 7.28
M-Score: -2.64
WACC vs ROIC
7.05%
18.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 15.38
WX's Operating margin (%) is ranked higher than
93% of the 249 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.55 vs. WX: 15.38 )
WX' s 10-Year Operating margin (%) Range
Min: -8.26   Max: 25.87
Current: 15.38

-8.26
25.87
Net-margin (%) 16.63
WX's Net-margin (%) is ranked higher than
97% of the 249 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.38 vs. WX: 16.63 )
WX' s 10-Year Net-margin (%) Range
Min: -25.33   Max: 27.18
Current: 16.63

-25.33
27.18
ROE (%) 15.31
WX's ROE (%) is ranked higher than
91% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. WX: 15.31 )
WX' s 10-Year ROE (%) Range
Min: -26.63   Max: 226.96
Current: 15.31

-26.63
226.96
ROA (%) 11.04
WX's ROA (%) is ranked higher than
94% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. WX: 11.04 )
WX' s 10-Year ROA (%) Range
Min: -18.88   Max: 72.95
Current: 11.04

-18.88
72.95
ROC (Joel Greenblatt) (%) 27.65
WX's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. WX: 27.65 )
WX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -17.71   Max: 73.69
Current: 27.65

-17.71
73.69
Revenue Growth (3Y)(%) 21.20
WX's Revenue Growth (3Y)(%) is ranked higher than
96% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. WX: 21.20 )
WX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 10.8   Max: 159.6
Current: 21.2

10.8
159.6
EBITDA Growth (3Y)(%) 13.20
WX's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. WX: 13.20 )
WX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 102.7
Current: 13.2

0
102.7
EPS Growth (3Y)(%) 8.80
WX's EPS Growth (3Y)(%) is ranked higher than
80% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. WX: 8.80 )
WX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 45
Current: 8.8

0
45
» WX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

WX Guru Trades in Q1 2014

Ron Baron 210,500 sh (+25.90%)
Sarah Ketterer 157,500 sh (+13.80%)
Columbia Wanger 3,334,900 sh (+11.76%)
John Hussman Sold Out
Mario Gabelli 59,700 sh (-8.44%)
Jim Simons 112,801 sh (-25.30%)
» More
Q2 2014

WX Guru Trades in Q2 2014

Jim Simons 127,500 sh (+13.03%)
Columbia Wanger 3,361,141 sh (+0.79%)
Mario Gabelli 57,200 sh (-4.19%)
Ron Baron 201,500 sh (-4.28%)
Sarah Ketterer 126,000 sh (-20.00%)
» More
Q3 2014

WX Guru Trades in Q3 2014

Jim Simons 235,300 sh (+84.55%)
Sarah Ketterer 180,700 sh (+43.41%)
Ron Baron 201,500 sh (unchged)
Mario Gabelli 57,200 sh (unchged)
Columbia Wanger 3,348,020 sh (-0.39%)
» More
Q4 2014

WX Guru Trades in Q4 2014

Ron Baron 251,500 sh (+24.81%)
Mario Gabelli 57,200 sh (unchged)
Sarah Ketterer 180,700 sh (unchged)
Columbia Wanger 3,334,742 sh (-0.40%)
Jim Simons 119,200 sh (-49.34%)
» More
» Details

Insider Trades

Latest Guru Trades with WX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on WuXi PharmaTech (Cayman) Inc

Baron Funds Comments on WuXi PharmaTech - Feb 24, 2014

Shares of WuXi PharmaTech (Cayman) Inc. (WX) were strong in the fourth quarter. As the largest Chinese Contract Research Organization (CRO), with an estimated 27% market share, WuXi is a beneficiary of increased pharma outsourcing activity to countries like China and India. Performance during the fourth quarter is attributable to above consensus financial results and a growing pipeline of contract research and manufacturing activity. We retain conviction in the company due to its high growth potential and strong relationships with leading pharmaceutical companies. (Anuj Aggarwal)

From Ron Baron (Trades, Portfolio)'s Baron Funds' fourth quarter 2013 commentary.

Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 25.00
WX's P/E(ttm) is ranked higher than
94% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 25.00 )
WX' s 10-Year P/E(ttm) Range
Min: 6.67   Max: 103.94
Current: 25

6.67
103.94
Forward P/E 14.75
WX's Forward P/E is ranked higher than
96% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 14.75 )
N/A
PE(NRI) 24.30
WX's PE(NRI) is ranked higher than
93% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 24.30 )
WX' s 10-Year PE(NRI) Range
Min: 6.62   Max: 102.94
Current: 24.3

6.62
102.94
P/B 3.40
WX's P/B is ranked higher than
75% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.82 vs. WX: 3.40 )
WX' s 10-Year P/B Range
Min: 1.11   Max: 10.64
Current: 3.4

1.11
10.64
P/S 4.30
WX's P/S is ranked higher than
70% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.63 vs. WX: 4.30 )
WX' s 10-Year P/S Range
Min: 0.79   Max: 11.05
Current: 4.3

0.79
11.05
PFCF 23.30
WX's PFCF is ranked higher than
92% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 23.30 )
WX' s 10-Year PFCF Range
Min: 10.85   Max: 141.12
Current: 23.3

10.85
141.12
POCF 15.30
WX's POCF is ranked higher than
90% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 431.57 vs. WX: 15.30 )
WX' s 10-Year POCF Range
Min: 6.59   Max: 297
Current: 15.3

6.59
297
EV-to-EBIT 22.03
WX's EV-to-EBIT is ranked higher than
86% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 22.03 )
WX' s 10-Year EV-to-EBIT Range
Min: -107.1   Max: 146.9
Current: 22.03

-107.1
146.9
PEG 0.49
WX's PEG is ranked higher than
100% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 0.49 )
WX' s 10-Year PEG Range
Min: 3.57   Max: 4.78
Current: 0.49

3.57
4.78
Shiller P/E 32.50
WX's Shiller P/E is ranked higher than
91% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 32.50 )
WX' s 10-Year Shiller P/E Range
Min: 18.48   Max: 64.93
Current: 32.5

18.48
64.93
Current Ratio 2.37
WX's Current Ratio is ranked higher than
69% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. WX: 2.37 )
WX' s 10-Year Current Ratio Range
Min: 0.79   Max: 5.75
Current: 2.37

0.79
5.75
Quick Ratio 2.20
WX's Quick Ratio is ranked higher than
71% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. WX: 2.20 )
WX' s 10-Year Quick Ratio Range
Min: 0.6   Max: 5.45
Current: 2.2

0.6
5.45
Days Inventory 38.31
WX's Days Inventory is ranked higher than
86% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 131.99 vs. WX: 38.31 )
WX' s 10-Year Days Inventory Range
Min: 23.55   Max: 66.63
Current: 38.31

23.55
66.63
Days Sales Outstanding 88.20
WX's Days Sales Outstanding is ranked higher than
70% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 74.31 vs. WX: 88.20 )
WX' s 10-Year Days Sales Outstanding Range
Min: 47.86   Max: 80.19
Current: 88.2

47.86
80.19

Valuation & Return

vs
industry
vs
history
Price/Net Cash 32.30
WX's Price/Net Cash is ranked higher than
83% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 32.30 )
WX' s 10-Year Price/Net Cash Range
Min: 11.88   Max: 29.18
Current: 32.3

11.88
29.18
Price/Net Current Asset Value 12.20
WX's Price/Net Current Asset Value is ranked higher than
85% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 12.20 )
WX' s 10-Year Price/Net Current Asset Value Range
Min: 4.31   Max: 61.52
Current: 12.2

4.31
61.52
Price/Tangible Book 4.00
WX's Price/Tangible Book is ranked higher than
82% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.60 vs. WX: 4.00 )
WX' s 10-Year Price/Tangible Book Range
Min: 1.45   Max: 9.09
Current: 4

1.45
9.09
Price/DCF (Projected) 2.30
WX's Price/DCF (Projected) is ranked higher than
86% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 2.30 )
WX' s 10-Year Price/DCF (Projected) Range
Min: 1.15   Max: 2.33
Current: 2.3

1.15
2.33
Price/Median PS Value 1.30
WX's Price/Median PS Value is ranked higher than
70% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. WX: 1.30 )
WX' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 2.74
Current: 1.3

0.29
2.74
Price/Peter Lynch Fair Value 4.50
WX's Price/Peter Lynch Fair Value is ranked higher than
90% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 4.50 )
WX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.25   Max: 4.32
Current: 4.5

0.25
4.32
Price/Graham Number 2.10
WX's Price/Graham Number is ranked higher than
92% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. WX: 2.10 )
WX' s 10-Year Price/Graham Number Range
Min: 0.86   Max: 4.93
Current: 2.1

0.86
4.93
Earnings Yield (Greenblatt) 4.40
WX's Earnings Yield (Greenblatt) is ranked higher than
85% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. WX: 4.40 )
WX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 12
Current: 4.4

0.7
12
Forward Rate of Return (Yacktman) 7.75
WX's Forward Rate of Return (Yacktman) is ranked higher than
68% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.73 vs. WX: 7.75 )
WX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.2   Max: 8.3
Current: 7.75

0.2
8.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:3W11.Germany,
WuXi PharmaTech (Cayman), Inc. was incorporated on March 16, 2007 and commenced operations and began offering pharmaceutical and biotechnology R&D outsourcing services in 2001. The Company is a pharmaceutical, biotechnology and medical device R&D services company, with operations in China and the United States. It provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers, which includes premier pharmaceutical, biotechnology and medical device companies. Its services are designed to assist its customers in shortening the cycle and lowering the cost of pharmaceutical and medical device R&D by providing cost-effective and efficient outsourcing solutions. Its primary China-based facilities include 1,127,000 square feet of facilities in the China (Shanghai) Pilot Free Trade Zone used for synthetic chemistry, biology, medicinal chemistry, DMPK, formulation, analytical development, manufacturing process chemistry, research manufacturing, bioanalytical services, genomics, and biologics drug discovery and development; an R&D center in Tianjin engaged in synthetic chemistry and medicinal chemistry; a facility in Wuhan providing services in synthetic chemistry and medicinal chemistry; a small-scale cGMP clinical manufacturing facility and a large-scale cGMP commercial manufacturing plant in the Jinshan district of Shanghai; a large-scale non-GMP manufacturing plant in Changzhou; a preclinical toxicology facility in Suzhou; a laboratory for manufacturing research reagents in Suzhou; and a biologics manufacturing facility in Wuxi. It also offers services in biologics and medical device testing in three FDA-registered facilities in the United States. The Company has two segments: Laboratory services and Manufacturing services. Laboratory services are provided for pharmaceutical, biotechnology and medical device companies. China-based laboratory services for pharmaceutical and biotechnology companies include services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical services, genomics, research reagent production, and clinical services, as well as services for discovery and development of biologics. U.S.-based laboratory services include testing services for biologics, medical devices, and combination products. Manufacturing services include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients, or APIs, for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologics. The Company offers testing and development services to ensure that a medical device is manufactured, packaged and sterilized in accordance with GMP guidelines. Its in vivo and in vitro toxicology testing includes bioco
» More Articles for WX

Headlines

Articles On GuruFocus.com
Baron Funds Comments on WuXi PharmaTech Feb 24 2014 
Columbia Management's Top 5 New Buys Amid Buoyant Outlook Aug 12 2013 
comment on WX Sep 15 2012 
Stocks That Are Cheaper Than Julian Robertson Bought Jan 06 2012 
Stocks That Julian Robertson Keeps Buying Dec 23 2011 
Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
Tiger Management Buys WX, CVC, THRX, Sells Apple Inc., Google Inc., Ebay Inc. Nov 15 2010 
WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services Dec 09 2008 

More From Other Websites
Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by... Mar 27 2015
Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by... Mar 27 2015
Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide Mar 25 2015
Falling Earnings Estimates Signal Weakness Ahead for WuXi PharmaTech (WX) - Tale of the Tape Mar 23 2015
WuXi PharmaTech Slumps: WX Falls 6.4% in Session - Tale of the Tape Mar 16 2015
S&P 500 Down Nearly 1% In Broad Stock Decline Mar 13 2015
WuXi PharmaTech To Build New Cell Therapy Manufacturing Facility for CAR T Cells and Other Cancer... Mar 12 2015
WuXi PharmaTech To Build New Cell Therapy Manufacturing Facility for CAR T Cells and Other Cancer... Mar 12 2015
Stocks Drop On Rate-Hike Fears; Big Lots Up On Earnings Mar 06 2015
Stocks Down In Afternoon; Miners, Utilities Take Hit Mar 06 2015
Stocks Extend Losses At Midday; WuXi PharmaTech Dives Mar 06 2015
Wuxi Pharmatech Cayman Inc Earnings Call scheduled for 8:00 am ET today Mar 06 2015
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results Mar 05 2015
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results Mar 05 2015
Q4 2014 Wuxi Pharmatech Cayman Inc Earnings Release - After Market Close Mar 05 2015
WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA Feb 27 2015
WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA Feb 27 2015
WuXi PharmaTech Enters into Syndicated Loan Agreement Feb 18 2015
WuXi PharmaTech Enters into Syndicated Loan Agreement Feb 17 2015
WuXi PharmaTech Schedules Fourth-Quarter 2014 Earnings Release Feb 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK